Month: June 2026
PrimeC was associated with changes across multiple biomarkers spanning key neurodegenerative disease pathways, providing early biological evidence consistent with potential target engagement Findings support continued development of PrimeC’s multi-target approach in Alzheimer’s disease Excerpt from the Press Release: CAMBRIDGE, Mass., June 25, 2026 /PRNewswire/ — NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a late-clinical stage biotechnology…
Collaboration combines Voro’s tumor-activated biologics platform and T-cell engager (TCE) expertise with Alloy’s antibody discovery and TCE engineering capabilities to develop novel tumor-selective immunotherapies Excerpt from the Press Release: SAN DIEGO & BOSTON–(BUSINESS WIRE)–Voro Therapeutics, a biotechnology company developing tumor-activated biologics designed to improve the therapeutic index of immune therapies, and Alloy Therapeutics, a biotechnology…
Clearance advances 8M2D, designed to inhibit β-amyloid production rather than clear plaque after it forms; first participant expected to be dosed in late 2026 Excerpt from the Press Release: LA JOLLA, CA / ACCESS Newswire / June 17, 2026 / The U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application…
Excerpt from the Press Release: CAMBRIDGE, Mass. and HONG KONG, June 17, 2026 /PRNewswire/ — Insilico Medicine (“Insilico”, HKEX: 3696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced it has achieved the first clinical milestone in its co-development collaboration with Hygtia Therapeutics with the completion of first-in-human dosing in the Phase…
Lead Cell Therapy Demonstrated Complete Tumor Clearance and 100% Long-Term Survival in Preclinical Ovarian Cancer Models; Multiple Regulatory, Manufacturing and Clinical Catalysts Expected Through 2027 Excerpt from the Press Release: CAMBRIDGE, Mass., June 17, 2026 (GLOBE NEWSWIRE) — Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer…
Collaboration aims to identify biomarkers predictive of antibody-drug conjugate (ADC) treatment response using 10x’s single cell and spatial platforms Excerpt from the Press Release: PLEASANTON, Calif., June 17, 2026 /PRNewswire/ — 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced a research collaboration with Cleveland…